| Market Cap | 143.18M | P/E | - | EPS this Y | -2.90% | Ern Qtrly Grth | - |
| Income | -112.77M | Forward P/E | -0.86 | EPS next Y | -30.50% | 50D Avg Chg | -21.00% |
| Sales | 88.46M | PEG | -0.78 | EPS past 5Y | - | 200D Avg Chg | -60.00% |
| Dividend | N/A | Price/Book | 0.91 | EPS next 5Y | 2.70% | 52W High Chg | -81.00% |
| Recommedations | 1.60 | Quick Ratio | 2.44 | Shares Outstanding | 97.13M | 52W Low Chg | 7.00% |
| Insider Own | 27.74% | ROA | -25.54% | Shares Float | 64.35M | Beta | 0.51 |
| Inst Own | 55.35% | ROE | -115.00% | Shares Shorted/Prior | 3.85M/3.67M | Price | 1.65 |
| Gross Margin | -77.23% | Profit Margin | -127.48% | Avg. Volume | 880,795 | Target Price | - |
| Oper. Margin | -122.27% | Earnings Date | Nov 7 | Volume | 347,056 | Change | -2.94% |
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
| HC Wainwright & Co. | Buy | Aug 6, 24 |
| HC Wainwright & Co. | Buy | Jul 25, 24 |
| HC Wainwright & Co. | Buy | May 22, 24 |
| HC Wainwright & Co. | Buy | May 2, 24 |
| HC Wainwright & Co. | Buy | Apr 22, 24 |
| HC Wainwright & Co. | Buy | Mar 8, 24 |
| Piper Sandler | Overweight | Dec 11, 23 |
| HC Wainwright & Co. | Buy | Dec 11, 23 |
| Cantor Fitzgerald | Overweight | Oct 10, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Malin Life Sciences Holdings L... | 10% Owner 10% Owner | Aug 08 | Buy | 3.50 | 2,150,000 | 7,525,000 | 11,835,673 | 08/10/22 |
| Ostertag Eric | Executive Chairman Executive Chairman | Aug 08 | Buy | 3.50 | 142,857 | 500,000 | 838,824 | 08/10/22 |
| Ingalls Kerry D. | Chief Operating Offi.. Chief Operating Officer | Mar 16 | Buy | 3.98 | 3,000 | 11,940 | 55,000 | 03/18/22 |
| Malin Life Sciences Holdings L... | - - | Nov 24 | Buy | 6.86 | 39,362 | 270,023 | 9,632,592 | 11/29/21 |
| Malin Life Sciences Holdings L... | - - | Nov 19 | Buy | 7.11 | 25,729 | 182,933 | 9,593,230 | 11/23/21 |
| Malin Life Sciences Holdings L... | - - | Nov 16 | Buy | 7.18 | 379,376 | 2,723,920 | 9,567,501 | 11/18/21 |
| Ostertag Eric | Chief Executive Offi.. Chief Executive Officer | Sep 15 | Sell | 8.14 | 20,000 | 162,800 | 180,696 | 09/15/21 |
| Ostertag Eric | Chief Executive Offi.. Chief Executive Officer | Sep 15 | Option | 5.16 | 21,281 | 109,810 | 675,415 | 09/15/21 |
| Ostertag Eric | Chief Executive Offi.. Chief Executive Officer | Sep 03 | Sell | 8.4 | 112,411 | 944,252 | 3,377,085 | 09/03/21 |